| Name | Pridopidine |
| Description | Pridopidine (FR310826), a dopamine (DA) stabilizer, acts as a low affinity dopamine D2 receptor (D2R) antagonist, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model. |
| Animal Research | Sprague Dawley rats (n = 6) were treated daily by oral gavage with pridopidine (60 mg/kg) over 10 days. Six control Sprague Dawley rats were vehicle-treated. On the 10th day, 90 min following the last drug administration, brains were removed and RNA was isolated from the striatum of each rat and was analyzed using Affymetrix Rat 230_2 arrays. The gene expression data from 12 striatum samples was RMA normalized with affy package v1.42.3 in R v3.1.2. Probesets were annotated . The limma package v3.18.13 in R v3.1.3 was used to test if relevant calcium-related genes were differentially expressed between the two groups of biological replicates and multiple hypothesis testing was corrected for using the Bonferroni correction. Limma employs an empirical Bayes method to moderate standard error . When a gene had multiple probesets, the probeset with the highest absolute value of fold change was reported[1]. |
| In vivo | The actions of pridopidine were mediated by S1R and led to normalization of ER Ca2+ release, ER Ca2+ levels and spine SOC entry in YAC128 MSNs. This is a new potential mechanism of action for pridopidine, highlighting S1R as a potential target for HD therapy. Upregulation of striatal proteins that regulate calcium, including calbindin and homer1a, upon chronic therapy with pridopidine, may further contribute to long-term beneficial effects of pridopidine in HD[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 45 mg/mL (159.91 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (7.11 mM), Sonication is recommended.
|
| Keywords | Pridopidine | Inhibitor | inhibit | FR-310826 | FR 310826 | DopamineReceptor | Dopamine Receptor | Dopamine | ASP-2314 | ASP 2314 | ACR-16 | ACR 16 |
| Inhibitors Related | Trifluoperazine dihydrochloride | Olanzapine | Clozapine N-Oxide | Mirtazapine | Butyrophenone | Promazine hydrochloride | Octopamine hydrochloride | L-DOPA | Creatine | Oxolinic acid | Mianserin hydrochloride | Fluphenazine dihydrochloride |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Membrane Protein-targeted Compound Library | ReFRAME Related Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Neuroprotective Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |
United States
